News ZEN Graphene Solutions Develops Novel Graphene-Based Potential Treatment for Bacterial and Viral Infections in Humans
Guelph, Ontario--(Newsfile Corp. - December 22, 2020) - ZEN Graphene Solutions Ltd.(TSXV: ZEN) (OTC Pink: ZENYF) ("ZEN" or the "Company") is pleased to announce that it has developed a potential graphene-based antibiotic, antiviral and antifungal compound. Recently received testing results from the University Health Network/Mount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens including, upper and lower respiratory tract infections - where COVID-19 is a major contributor - as well as drug resistant organisms. Testing was conducted by Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief & Infectious Disease Specialist at Mount Sinai Hospital. Dr. Mazzulli is also a Professor at the Departments of Laboratory Medicine & Pathobiology and Medicine at the University of Toronto.
Greg Fenton, CEO commented, "This broad-spectrum compound is a novel solution that could have an impact on infectious disease management. It has the potential to act as a targeted treatment for multi-drug resistant organisms (MDR) as well. As in previously released results on the effectiveness of a similar compound against COVID-19, this graphene-based treatment could be against viral infections. We will be exploring its use not only in the fight against the current global pandemic, but also against numerous other pathogens."
"Based on this breakthrough and an urgent need for such treatments, we will seek immediate collaborations with potential pharmaceutical partners to optimize the delivery mechanisms to target infections in general and especially those common in the respiratory tract."
Highlights:
- Graphene compound is 99.9% effective against both gram-positive and gram-negative aerobic bacteria
- Graphene compound is 99.9% effective against Candida Albicans (fungus/yeast)
- Extremely low Minimum Inhibitory Concentrations (MIC) leading to the potential use in humans
- ZEN has filed a provisional patent on these graphene compounds
- Additional testing required to determine full spectrum of activity against other pathogens
- Cytotoxicity studies are currently underway
- Potential use to treat infection of upper and lower respiratory tract
- Potential role in ear, eye, and fungal infections